$1.05
-0.06 (-5.41%)
Open$1.12
Previous Close$1.11
Day High$1.12
Day Low$1.04
52W High$7.19
52W Low$1.07
Volume—
Avg Volume267.6K
Market Cap31.06M
P/E Ratio—
EPS$-5.90
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+3,758.1% upside
Current
$1.05
$1.05
Target
$40.51
$40.51
$28.40
$40.51 avg
$50.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 6.30M | 6.48M | 4.92M |
| Net Income | -1,316,650 | -1,573,823 | -1,131,717 |
| Profit Margin | -20.9% | -24.3% | -23.0% |
| EBITDA | -2,363,922 | -2,326,744 | -1,866,701 |
| Free Cash Flow | -1,722,588 | -1,580,767 | -1,263,847 |
| Rev Growth | -2.8% | +6.4% | +0.2% |
| Debt/Equity | 0.17 | 0.14 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |